Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

被引：0
|
作者：
Venkatesh, Priyanka [1 ,2 ]
Khasawneh, Ghena [1 ,3 ]
Hashmi, Hamza [1 ,4 ]
Alkharabsheh, Omar [1 ,5 ]
Paul, Barry [1 ,6 ]
Skikne, Barry S. [1 ,7 ]
Mahmoudjafari, Zahra [1 ,7 ]
Ahmed, Nausheen [1 ,7 ]
Abdallah, Al-Ola [1 ,7 ]
Atrash, Shebli [1 ,6 ]
机构：
[1] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[2] Univ Kansas, Internal Med, Med Ctr, Kansas City, KS USA
[3] Jordan Univ Sci & Technol, Irbid, Jordan
[4] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA
[5] Univ S Alabama, Mobile, AL USA
[6] Atrium Hlth, Levine Canc Inst, Plasma Cell Disorders Sect, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[7] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [22] SAFETY OF RAPID DARATUMUMAB INFUSION IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Attardi, E.
    Antonioli, E.
    Staderini, M.
    Messeri, M.
    Buzzichelli, A.
    Nencini, V.
    Fani, A.
    Bosi, A.
    HAEMATOLOGICA, 2019, 104 : 65 - 66
  • [23] Safety of rapid daratumumab infusion in relapsed and refractory multiple myeloma
    Antonioli, Elisabetta
    Attardi, Enrico
    Staderini, Michela
    Nozzoli, Chiara
    Buzzichelli, Alessandra
    Messeri, Maria
    Bosi, Alberto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E141 - E141
  • [24] Therapy of relapsed and relapsed refractory multiple myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 113 - 113
  • [25] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    EJHAEM, 2021, 2 (01): : 56 - 65
  • [26] Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma
    Chen, Pingping
    Ma, Jiexian
    Qian, Wensi
    Wu, Min
    Shen, Lin
    Xie, Yanhui
    MINERVA PEDIATRICS, 2024, 76 (01): : 121 - 123
  • [27] Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Galusic, Davor
    Krecak, Ivan
    Blaslov, Viktor
    Opara, Andela Krstulovic
    Valkovic, Toni
    Kinda, Sandra Basic
    BIOMEDICINES, 2025, 13 (01)
  • [28] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary E.
    Feng, Huaibao
    Brun, Nikolai Constantin
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [29] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
    Plesner, T.
    Arkenau, H. T.
    Lokhorst, H. M.
    Gimsing, P.
    Krejcik, J.
    Lemech, C.
    Minnema, M. C.
    Lassen, U.
    Ahmadi, T.
    Yeh, H.
    Guckert, M.
    Brun, N. C.
    Lisby, S.
    Basse, L.
    Palumbo, A.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 104 - 104
  • [30] Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Rajeeve, Sridevi
    Jurgens, Eric
    Nishimura, Noriko
    Farzana, Tasmin
    Firestone, Ross
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Tan, Carlyn
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S46
12345